BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 29038282)

  • 1. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
    Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
    Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
    Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
    Moore DJ; Jain S; Dubé MP; Daar ES; Sun X; Young J; Corado K; Ellorin E; Milam J; Collins D; Blumenthal J; Best BM; Anderson P; Haubrich R; Morris SR
    Clin Infect Dis; 2018 May; 66(10):1566-1572. PubMed ID: 29228144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
    AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
    Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
    PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
    Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
    Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
    Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
    Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
    Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
    Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
    Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.